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Degeneration and Reversed Paw Numbness in a Wistar Rat 
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Painful diabetic peripheral neuropathy (DPN) is prevalent amidst diabetic patients. It develops with a background of long-
standing hyperglycaemia, metabolic derangements and oxidative stress. Vitamin C an aqueous phase antioxidant which may help 
in combating oxidative stress. Vitamin C depletion occurs in diabetes and this has been reported to be associated with spinal and 
musculoskeletal pain.  Therefore, this study was conducted to investigate the effect of vitamin C administration on neuropathic 
pain and peripheral nerve in DPN. Thirty wistar rats (180-200g) were grouped (n=10) into control (C), diabetic and vitamin C 
treated diabetic. Diabetic neuropathy was induced using 20% fructose and 150mg/kg.ip alloxan. Vitamin C (1g/kg.p.o) treatment 
via oral-canula lasted for two weeks. Neuropathy was assessed using tail flick and formalin paw lick tests. Peripheral nerve 
histology and sympathetic activity were assessed using light microscopy and tyrosine hydroxylase (TH) immunohistochemistry 
respectively. Oxidative and nitrosative stress markers (SOD, MDA, GSH, VC & NO) were evaluated using spectrophotometry. 
Hyperalgesia, paw numbness, sciatic nerve degeneration and reduced sympathetic activity were observed in diabetic rats showing 
peripheral neuropathy. However, these were reversed in vitamin C treated diabetic rats via mechanism related to upregulation of 
tyrosine hydroxylase activities and downregulation of oxidative and nitrosative stress, as SOD, NO and MDA were significantly 
(p<0.01) reduced, while GSH, VC and TH were increased (p<0.05) in Vitamin C treated rats.  Thus, vitamin C may be an 
effective adjunct therapy for neuropathic pain relief, restoration of normal sensation in lower limbs and amelioration of diabetic 
peripheral neuropathy. 
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INTRODUCTION 
 
Diabetic neuropathy is a heterogenous set of both clinical and 
sub-clinical manifestations of diseases connected with the 
peripheral nervous system, which arises as a complication of 
diabetes mellitus. This can affect both the somatic and 
autonomous nervous systems (Haslbeck et al. 2004). Diabetic 
neuropathies are proven to be heterogenous, not only by their 
symptoms, but also their pattern of neurologic involvement, 
underlying mechanisms, pathologic alterations, course, and 
risk co-variates. Neuropathy in diabetes can be classified into 
(multi)focal and generalized (or symmetric) varieties of 
neuropathy. Multifocal neuropathies comprise of lumbosacral, 
cervical radiculoplexus, mononeuropathy and thoracic 
neuropathies. On the other hand, classified under 
generalised/symmetric neuropathies are: Autonomic and 
peripheral neuropathies. Peripheral neuropathy is regarded the 
commonest kind of diabetic neuropathy that is often 
associated with pain and peripheral nerve dysfunction. 
 About thirty percent of persons living with type 1 or type 
2 diabetes are reported to have the painful symptoms of 
peripheral neuropathy. Diabetic peripheral neuropathy (DPN) 
can be symptomatic or asymptomatic with nearly 50% of 
patients having symptoms in the feet, lower limbs and 
sometimes in the hands. These include burning, tingling, 
sharp, shooting, lancinating, stabbing or electrical sensations. 
In addition, there could be hyperaesthesia, paraesthesia, 
prickling, severe aching pain and unresponsiveness 
(numbness) all of which develops proximally from the feet 
and hands (Dyck et al. 2006, Tesfaye et al. 2013).  These 
symptoms are generally accompanied with pain, hyperalgesia 
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 Neuropathic pain reduces the quality of life of patients, 
their physical mobility, and general wellbeing. Diabetic 
neuropathy usually originates and progresses with a history of 
established hyperglycaemia, oxidative stress, metabolic 
derangements, lipid alterations, accumulated advanced 
glycation end products, and other metabolic abnormalities 
(Dyck et al. 2006, Rajan et al. 2014). Evidently, anti-oxidant 
enzymes are found to be reduced in diabetic nerves compared 
with non-diabetic nerves. This, coupled with increased 
production of oxidative radicals, contribute to nerve blood 
flow and transmission deficits, diminished neurotrophic 
support and morphological abnormalities characteristic of 
DPN (Zherebitskaya et al 2009). In the light of these, 
inhibition of oxidative stress may attenuate the neuropathic 
complications of diabetes. Studies have shown that 
antioxidants reduced neuropathy pain scores without the side 
effects of opioids or anticonvulsants often used in the 
treatment of pain associated with neuropathy (Ziegler et al. 
2004). Thus, antioxidants might be a better alternative or 
adjunct in the management of diabetic neuropathy.  Vitamin 
C is an aqueous phase antioxidant reported to be deficient in 
diabetic subjects and its depletion has been linked with both 
spinal and musculoskeletal pains (Dionne et al. 2016). It is a 
co-factor in the fusion of catecholamine neurotransmitters 
and, as a result, is implicated in neuromodulation (May et al. 
2013). Furthermore, it is a co-factor in the fusion of opioid 
peptides and amidated neuropeptide such as endomorphine 
with potent opioid activity (Carr and McCall, 2017). Thus, 
vitamin C may possess potential analgesic and 
neuroprotective properties in addition to its anti-oxidative 
properties. However, the use of vitamin C alone in the 
treatment of peripheral neuropathic pain symptoms is yet to be 
validated scientifically thus the need for this work. This study, 
therefore, investigates the effect of vitamin C on neuropathic 
pain and peripheral nerve in a rat model of diabetic 
neuropathy. 
 
MATERIALS AND METHODS 
 
Animal grouping and Diabetic neuropathy induction: 
Thirty Wistar rats weighting 180-200g were randomly allotted 
into control (C), diabetic neuropathy (DN) and VC-treated-
DN (DNVC) groups with n=10. The Control group received 
water, while other groups took 20% w/v fructose enriched 
water, alongside their normal feeding, for two weeks. 
Thereafter, DN and DNVC rats received an injection of 
150mg/kg alloxan (5% w/v) in normal saline solution while 
control rats received the normal saline vehicle 
intraperitoneally (Fabiyi-Edebor and Fasanmade 2019). 
Twenty-four hours after, rats having fasting blood glucose 
greater than 250mg/dl were regarded diabetic. Diabetic rats 
are considered as a prototype of diabetic neuropathy (Lee-
Kubli et al. 2014, Mehta et al. 2017). Next, DNVC group 
received 1g/kg/day of vitamin C (ascorbic acid) via oral 
cannula for two weeks (Fabiyi-Edebor and Fasanmade, 2019). 
On the last day of the treatment period, experiments were 
conducted on the rats to research into the effects of vitamin C 
on DPN pain. The animals were cared for according to the 
handbook on the care and use of laboratory animals (National 
Academies Press 2011) and the experiments approval of the 
animal ethical committee of Afe Babalola University. 
 
Hyperalgesia Assessment: Thermal and mechanical 
hyperalgesia response tests were used to assess peripheral 
neuropathic pain in the rats. (Lee-Kubli et al 2014). Response 
to thermal hyperalgesia was done using the tail flick test. Five 
centimetres of the rats’ tail from the tip was dipped in hot 
water maintained at 55±1◦c. The tail withdrawal latencies were 
taken at 0, 15, 30, 60, and 90 minutes intervals (Onasanwo et 
al. 2012).  
 Mechanical hyperalgesia was done using formalin paw lick 
test. Twenty microliters of formalin were injected into the 
planter surface of the left hind paw of the rats.  The formalin 
paw lick response test is bi-phasic. Following formalin 
injection, the early phase lasted for the first fifteen minutes, 
but the late phase occurred between fifteen- and sixty-minutes 
following formalin injection. The time spent by the rats in 
licking the injected paws and the number of times the rats 
licked the injected paws were observed and measured as an 
index of mechanical hyperalgesia (Onasanwo et al 2012). The 
experiment was carried out in a translucent plastic chamber 
(30x30x30) cm), with a mirror placed at the bottom for an 
unhindered view of the animals.  
 
Oxidative stress studies: Markers of oxidative stress such as 
superoxide dismutase (SOD), Gluthatione (GSH), lipid 
peroxidation or malondialdehyde (MDA), Nitric oxide (NO) 
and vitamin C (VC) were assayed for in sera samples of the 
rats using spectrophotometry. 
 
Histological assessment of the sciatic nerve: Cross sections 
of the sciatic nerve tissue were fixed in 10% formaldehyde 
solution, rooted in paraffin wax blocks and divided into 5µm 
slices with the use of a microtome. The samples were 
respectively stained with both eosin and hematoxylin. The 
stained slides were mounted and observed microscopically. A 
microscopic report of all the samples was, thus, graded as 
mild, moderate or severe neuropathy for the sciatic nerves. 
 
Immunohistochemical studies on the sciatic nerve: 
Tyrosine hydroxylase (TH) antibody was used to stain 
paraffin sections of the sciatic nerves of the rats. 
Dopaminergic neurons of the sciatic nerves were stained 




The results presented as mean + SEM were subjected to 




There was no considerable difference in tail flick latency 
between the vitamin C treated diabetic group and control 
(p>0.05) at 0,15 and 30 minutes after vitamin C 
administration. However, at 60minutes, DN+VC tail flick 
latency was considerably (p>0.05) greater than control. The 
untreated diabetic group showed significant (p<0.001) 
decrease in tail flick latencies at t=0,15,30,60 minutes 
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compared with ascorbic acid treated diabetic and control 
groups. The diabetic rats did not show significant paw lick 
response to the formalin test; however, significant response 
was observed in vitamin C treated rats (Figure 2). The number 
and duration of paw licks were considerably (p<0.01) reduced 
in DNVC rats unlike control but greater (p<0.05) compared 
with diabetic rats.  
 Biochemical analysis revealed that MDA, SOD and NO 
were significantly(P<0.001) increased while GSH and VC 
were significantly (p<0.01) decreased in diabetic rats. In 
contrast, these variables in VC treated rats were similar to 
control values except for GSH that was greater (P<0.05) in 
DNVC than control (Figure 3).  
 Plate 1 shows severe histopathological changes in the 
sciatic nerves of diabetic rats with mild alteration in vitamin 
C treated rats while Plate 2 shows tyrosine hydroxylase 









Figure 1:  
Tail flick latency of control, diabetic 
(DN) and vitamin C treated diabetic 
(DNVC) rats at (a) 0 minutes, (b) 15 
minutes, (c) 30 minutes, and (d) 60 
minutes after oral administration of 
vitamin C. The results are shown as 
mean ± SEM, n=10, ***p<0.001, 
*p<0.05 significantly different from 
control.  ++++ p< 0.001 significantly 
different from DNVC. 
 
Figure 2:  
Mechanical hyperalgesia using 
the formalin paw lick test in 
diabetic and DNVC rats. The 
Results are shown as mean ± 
SEM, n=10, ***p<0.001, 
*p<0.05 significantly different 
from control. + p< 0.05 
significantly different from VC 
treated. 
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Figure 3:  
Biochemical analysis of diabetic and VC 
treated rats. 
The results are shown as mean ± SEM, 
n=10, ***p<0.001, ** p< 0.01, *p<0.05 
significantly different from control, + p< 
0.001 significantly different from DNVC. 
Plate 1:  
Photomicrograph showing the longitudinal section of the 
sciatic nerves of control (A), diabetic (B) and vitamin C 
treated (C) rats, stained with H&E. Magnification: x400. 
 
Plate 2:  
Photomicrograph showing tyrosine hydroxylase activity in the sciatic nerves of A-
control, B-diabetic and C- vitamin C treated rats immune-reactively stained with 
anti-TH antibody. (Magnification = 400x). D – nuclei count of the slides 
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Diabetic peripheral neuropathy has been established in animal 
models of diabetes including type II diabetes induced using a 
combination of diet and diabetogenic agents (Mehta et al 
2017). It is usually associated with symptoms similar to that 
observed in patients with diabetic neuropathy. These 
symptoms include allodynia, slow nerve conduction velocity 
(NCV), progressive sensory deficits and hyperalgesia and may 
be accompanied with neuropathic pain and/or sensory or 
motor loss in the extremities (Mehta et al. 2017, Ziegler 1999).  
Neuropathic pain in diabetic animals can be assessed using 
thermal, chemical or mechanical hyperalgesia and/or 
allodynia.  Hyperalgesia have been reported in diabetic 
animals within a week or more of diabetes (Mehta et al 2017). 
In this study, thermal hyperalgesia was observed in the second 
week of diabetes induction using tail flick test. Hyperalgesia 
suggest sensitization of central and peripheral nociceptive 
neurons which engender a cascade of effects experienced as 
pain. However, tail flick latency was increased in vitamin C 
treated rats, thus revealing the anti-nociceptive /analgesic 
effect of vitamin C. The mechanism may be by inhibiting the 
central mechanism of pain through prevention of oxidation 
since enhanced (Campbell & Meyer 2006). Oxidative damage 
to peripheral nerves causes hyperexcitability in the afferent 
nociceptors and central neurons leading to the generation of 
spontaneity within the axons and dorsal root ganglions of the 
nerves contributing to the neuropathic pain associated with 
diabetic neuropathy (Yorek 2003). 
 The behavioral response to formalin paw lick test consists 
of a severe phase (Phase I) of a short-lasting response, which 
is believed to indicate the activity of C-fiber afferent 
nociceptors. The severe phase is followed by a continuous 
prolonged response (Phase II) after a short quiescent period. 
This is believed to be due to central sensitization of the spinal 
dorsal horn neurons because of the initial input from C-fiber 
nociceptive afferents during the early phase (Coderra et al 
1993; Gong et al 2014). In the two phases of the formalin paw 
licking test conducted in this study, diabetic rats showed 
numbness (very little or no paw licking response) in their foot 
when ‘injected with formalin. However, sensation was 
restored to the foot of diabetic rats treated with vitamin C. This 
was demonstrated as an increase in paw licking activity of the 
vitamin C treated rats compared with the almost absent paw 
lick response in diabetic rats.  Thu, vitamin C may have effect 
on both central and peripheral nervous system. Vitamin C has 
also been shown to concentrate in neurons in both central and 
peripheral nervous system. Its functions therein functions 
include peptide amidation, myelin formation, antioxidant 
function, synaptic potentiation, neuronal function, nerve 
regeneration and maturation among others (Rosa et al. 2005; 
May 2012). In addition, vitamin C deficiency has been 
reported to cause peripheral neuropathy and hypomyelination 
(Gess et al. 2011, Staff & Windebank 2014). Thus, 
hyperglycemia induced oxidative stress coupled with vitamin 
C deficiency in diabetic condition could bring about peripheral 
nerve damage via auto-destruction of nerves (Staff & 
Windebank 2014). This was evident in this study by the 
increases in oxidative stress markers; decrease in antioxidants, 
for example glutathione and vitamin C; and structural damage 
to the sciatic nerve in diabetic rats. The structural damage in 
the diabetic sciatic nerve was shown by the disarray in the 
normal parallel arrangement of the nerve fibres, degeneration 
of the nerve fibres, reduced tyrosine hydroxylase synthesis 
and reduced nuclei count.  Tyrosine hydroxylase activity 
which was greatly reduced in diabetic sciatic nerve shows 
abnormally reduced sympathetic activities however, upon 
vitamin C administration, tyrosine hydroxylase secretion and 
thus sympathetic activities was elevated.   In addition, vitamin 
C treatment showed nerve repair and regeneration. The 
mechanism through which vitamin C wields this 
neuroprotective effect may be by reducing oxidative stress.  
 Oxidative stress has been shown to cause nerve damage in 
diabetes and is the most understood process of development 
of diabetes to diabetic neuropathy (Yorek 2003, Staff & 
Windebank 2014). The mechanisms that are implicated in 
oxidative stress-induced neural dysfunctions comprise 
increased reactive nitrogen species, reduction in cellular 
antioxidants, DNA damage, lipid peroxidation, and generation 
of reactive oxygen species (Ho et al. 2006; (Obrosova et al. 
2007). Increased nitrogen and reactive oxygen species are able 
to damage lipids existing in the myelinated structures of 
nerves, thereby resulting in the loss of axons as well as the 
disruption of the microvasculature in the nervous system 
(Casellini & Vinik 2006). However, vitamin C administration 
reduced increased reactive nitrogen species, reactive oxygen 
species, lipid peroxidation by reducing the levels of 
superoxide dismutase (SOD), nitric oxide (NO) and 
malondialdehyde (MDA) respectively. In addition, 
antioxidant status was improved by increasing glutathione and 
replenishing depleted vitamin C. 
 In conclusion, Vitamin C seems to be an efficacious 
adjunctive therapy for neuropathic pain relief, preventing foot 
numbness and ameliorating diabetic peripheral neuropathy 
due to its analgesic and neuroprotective effects through 
mechanisms that may be related to downregulation of 
oxidative stress and upregulation of tyrosine hydroxylase 
activities. However, human studies may be required to 
validate this effect of vitamin C on diabetic peripheral 
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